NCT02706535 - A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2016

Primary Completion Date

January 6, 2017

Study Completion Date

January 6, 2017

Conditions

Drug InteractionsNeoplasms

Interventions

DRUG

GSK525762 Besylate Tablets

GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.

DRUG

Itraconazole 200 mg

Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL

DRUG

Rifampicin 300 mg

Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore